The use of circulating biomarkers in early clinical trials in patients with cancer

被引：2

作者：

D'Arcangelo, Manolo ^{[1
,2
]}

Margetts, Jane ^{[2
]}

Greystoke, Alastair ^{[1
,2
]}

机构：

[1] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[2] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England

来源：

BIOMARKERS IN MEDICINE | 2015年 / 9卷 / 10期

关键词：

cancer; circulating free DNA; circulating tumor cells; pharmacodynamics biomarkers; tumor markers; PROSTATE-SPECIFIC ANTIGEN; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; MOLECULARLY TARGETED AGENTS; PROGRESSION-FREE SURVIVAL; BLOOD MONONUCLEAR-CELLS; TUMOR-CELLS; MESSENGER-RNA; PERIPHERAL-BLOOD; BREAST-CANCER;

D O I：

10.2217/bmm.15.51

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The development of targeted therapies has changed the approach to early oncological clinical trial design. Identification of patient populations most likely to derive benefit and the biologically effective dose are now as important as determination of the maximum tolerated dose. Completion of the 'pharmacological audit trail' highlights drugs most likely to progress through to license, so resources can be allocated appropriately. Key to the success of this changing model is the validation/qualification of circulating biomarkers. These might provide a readily accessible and dynamic picture of drug effect, tumor response and toxicity with minimum risk to patients. This review article examines circulating biomarkers currently used in early oncological clinical trials. It considers the evidence for their employment, limitations and challenges for future development.

引用

页码：1011 / 1023

页数：13

共 108 条

[1] Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].

Allard, WJ ;

Matera, J ;

Miller, MC ;

Repollet, M ;

Connelly, MC ;

Rao, C ;

Tibbe, AGJ ;

Uhr, JW ;

Terstappen, LWMM .

CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904

[2] The functions of animal microRNAs [J].

Ambros, V .

NATURE, 2004, 431 (7006) :350-355

[3]

[Anonymous], ANN ONCOL

[4] Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital [J].

Antoine, Daniel J. ;

Dear, James W. ;

Lewis, Philip Starkey ;

Platt, Vivien ;

Coyle, Judy ;

Masson, Moyra ;

Thanacoody, Ruben H. ;

Gray, Alasdair J. ;

Webb, David J. ;

Moggs, Jonathan G. ;

Bateman, D. Nicholas ;

Goldring, Christopher E. ;

Park, B. Kevin .

HEPATOLOGY, 2013, 58 (02) :777-787

[5]

Antonyak MA, 2014, METHODS MOL BIOL, V1165, P147, DOI 10.1007/978-1-4939-0856-1_11

[6] The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer [J].

Backen, Alison ;

Renehan, Andrew G. ;

Clamp, Andrew R. ;

Berzuini, Carlo ;

Zhou, Cong ;

Oza, Amit ;

Bannoo, Selina ;

Scherer, Stefan J. ;

Banks, Rosamonde E. ;

Dive, Caroline ;

Jayson, Gordon C. .

CLINICAL CANCER RESEARCH, 2014, 20 (17) :4549-4558

[7] Clinical utility of cytokeratins as tumor markers [J].

Barak, V ;

Goike, H ;

Panaretakis, KW ;

Einarsson, R .

CLINICAL BIOCHEMISTRY, 2004, 37 (07) :529-540

[8] Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer [J].

Board, Ruth E. ;

Williams, Victoria S. ;

Knight, Lucy ;

Shaw, Jacqueline ;

Greystoke, Alastair ;

Ranson, Malcolm ;

Dive, Caroline ;

Blackhall, Fiona H. ;

Hughes, Andrew .

CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V, 2008, 1137 :98-107

[9] MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer [J].

Boeri, Mattia ;

Verri, Carla ;

Conte, Davide ;

Roz, Luca ;

Modena, Piergiorgio ;

Facchinetti, Federica ;

Calabro, Elisa ;

Croce, Carlo M. ;

Pastorino, Ugo ;

Sozzi, Gabriella .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (09) :3713-3718

[10] Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells [J].

Boulay, A ;

Zumstein-Mecker, S ;

Stephan, C ;

Beuvink, I ;

Zilbermann, F ;

Haller, R ;

Tobler, S ;

Heusser, C ;

O'Reilly, T ;

Stolz, B ;

Marti, A ;

Thomas, G ;

Lane, HA .

CANCER RESEARCH, 2004, 64 (01) :252-261

← 1 2 3 4 5 6 7 8 9 10 →